C:\Program Files\Stnexp\Queries\10775675.str





chain nodes :
13 21 22 23 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19
chain bonds :
1-13 13-14 21-22 21-23 24-25 26-27 26-28
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-11 8-9 9-10 10-11 14-19 14-15 15-16
16-17 17-18 18-19
exact/norm bonds :
1-2 1-7 1-13 2-3 3-4 4-5 5-6 5-8 6-7 6-11 8-9 9-10 10-11 13-14 14-19 14-15
15-16 16-17 17-18 18-19 21-22 21-23 24-25 26-27 26-28

G1:C,O,S,N

G2:C,N

G3:[*1-*2],[*3-*4],[*5-*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

```
=> d his

     (FILE 'HOME' ENTERED AT 13:34:05 ON 17 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 13:34:46 ON 17 MAR 2006
L1             STRUCTURE UPLOADED
L2          14 S L1
L3         328 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 13:36:17 ON 17 MAR 2006
L4          33 S L3
L5          21 S L4 AND PATENT/DT
L6          12 S L4 NOT L5
L7           0 S L6 AND 2006/SO
L8           1 S L6 AND 2005/SO
L9           2 S L6 AND 2004/SO
L10          0 S L6 AND 2003/SO
L11          1 S L6 AND 2002/SO
L12         29 S L4 NOT (L8 OR L9 OR L11)

     FILE 'REGISTRY' ENTERED AT 13:37:19 ON 17 MAR 2006
L13     105383 S 6-6-7/SZ
L14      57439 S 5-6-7/SZ
L15        282 S L3 AND L13
L16          0 S L3 AND L14
L17         46 S L3 NOT L15

     FILE 'CAPLUS' ENTERED AT 13:40:07 ON 17 MAR 2006
L18          19 S L15
L19          17 S L18 NOT (L8 OR L9 OR L11)

=> d ibib abs hitstr total
```

L19 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:736256 CAPLUS
DOCUMENT NUMBER: 137:263078
TITLE: Preparation of tricyclic heterocyclic compounds as antagonists of tachykinin receptor
INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Tarui, Naoki; Kamo, Izumi; Shirai, Junya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074771	A1	20020926	WO 2002-JP2624	20020319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2002348289	A2	20021204	JP 2002-77248	20020319
PRIORITY APPLN. INFO.:			JP 2001-78567 A	20010319

OTHER SOURCE(S): MARPAT 137:263078
GI



I

AB Tricyclic heterocyclic compds. such as 6,8,9,10,11,13-hexahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,10-dione derivs. represented by the formula (I; wherein ring A represents a substituted pyridine ring; R2 represents hydrogen, halogeno, or optionally halogenated C1-6 alkyl; R3 represents hydrogen or C1-6 alkyl; R's are the same or different and each represents halogeno, optionally halogenated C1-6 alkyl, optionally halogenated C1-6 alkoxy, cyano, or hydroxy; m is an integer of 0 to 3; n is 1 or 2; and p is an integer of 0 to 3) or salts thereof or prodrugs of either are prepared These compds. have an excellent antagonistic effect on a tachykinin receptor, especially on a substance P receptor, and are useful for

improving micturition abnormality and for the prevention and/or treatment of substance P-related diseases pollakiuria (increased urinary frequency), urinary incontinence, asthma, rheumatoid arthritis, osteoarthritis (arthrosis deformans), pain, cough, pruritus (itching), chronic obstructive lung disease, irritable bowel diseases, vomiting, HIV infection, depression, anxiety neurosis, obsessive-compulsive neurosis, panic disorder, manic-depressive psychosis, or schizophrenia. Thus, (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-phenyl-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione was oxidized by m-chloroperbenzoic acid in CH2Cl2 and then was stirred with trimethylsilyl cyanide and Et3N in MeCN at 85° for 3 h to give (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-9-methyl-5-phenyl-6,13-dioxo-8,9,10,11-tetrahydro-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-2-carbonitrile (II). II in vitro inhibited the binding of [125I]substance P to substance P receptor of human lymphoblast cells with IC50 of 0.047 nM.

IT **461680-83-1P 461680-98-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic heterocyclic compds. as antagonists of tachykinin receptor (substance P receptor) for prevention and/or treatment of substance P-related diseases)

RN 461680-83-1 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-2-methoxy-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-98-8 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 2-chloro-7-[(3,5-dimethylphenyl)methyl]-5-(4-fluorophenyl)-7,8,9,10-tetrahydro-9-methyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **461680-85-3P 461680-88-6P 461680-90-0P**
461680-92-2P 461680-94-4P 461680-96-6P
461681-00-5P 461681-02-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic heterocyclic compds. as antagonists of tachykinin receptor (substance P receptor) for prevention and/or treatment of substance P-related diseases)

RN 461680-85-3 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-2-(methylthio)-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-88-6 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-2,9-dimethyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-90-0 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-2-carbonitrile, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9,10,12-hexahydro-9-methyl-6,12-dioxo-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-92-2 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 2-chloro-7-[(3,5-dimethylphenyl)methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-94-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,5-dimethylphenyl)methyl]-7,8,9,10-tetrahydro-2,9-dimethyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461680-96-6 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-2-carbonitrile, 7-[(3,5-dimethylphenyl)methyl]-6,7,8,9,10,12-hexahydro-9-methyl-6,12-dioxo-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461681-00-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,5-dimethylphenyl)methyl]-5-(4-fluorophenyl)-7,8,9,10-tetrahydro-2,9-dimethyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461681-02-7 CAPLUS
CN [1,4]Diazepino[1,2-g]-1,6-naphthyridine-5,11-dione, 10-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-7,8,9,10-tetrahydro-2,8-dimethyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **183549-88-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic heterocyclic compds. as antagonists of tachykinin receptor (substance P receptor) for prevention and/or treatment of substance P-related diseases)
RN 183549-88-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **461681-04-9P 461681-12-9P 461682-15-5P**
461682-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic heterocyclic compds. as antagonists of tachykinin receptor (substance P receptor) for prevention and/or treatment of substance P-related diseases)

RN 461681-04-9 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,5-dimethylphenyl)methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461681-12-9 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,5-dimethylphenyl)methyl]-5-(4-fluorophenyl)-7,8,9,10-tetrahydro-9-methyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461682-15-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, 1-oxide, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461682-17-7 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-7,8,9,10-tetrahydro-9-methyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

applicant

L19 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:575779 CAPLUS
DOCUMENT NUMBER: 137:125185
TITLE: Preparation of tricyclic benzodiazepines as vasopressin receptor antagonists
INVENTOR(S): Hoekstra, William J.; Dyatkin, Alexey B.; Maryanoff, Bruce E.; Matthews, Jay M.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 468,650, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103373	A1	20020801	US 2001-911605	20010724
US 6713475	B2	20040330		
TR 200102069	T2	20011121	TR 2001-200102069	19991221
PT 1147115	T	20040227	PT 1999-966495	19991221
ES 2207333	T3	20040516	ES 1999-966495	19991221
US 2004242866	A1	20041202	US 2004-775675	20040210
PRIORITY APPLN. INFO.:			US 1999-116358P	P 19990119
			US 1999-468650	B2 19991221
			US 2001-911605	A1 20010724

OTHER SOURCE(S): MARPAT 137:125185
GI



I



II

AB Title compds. [I or II; m = 0-1; with the proviso that if m = 0 or 1, then "HET" = 5-6 membered monocyclic aromatic ring system composed of carbon atoms and one heteroatom selected from N, O and S; A = CO, SO2, CH2; Y = CH2, CH; X = CH2, CH, NR3, S, O; Z = N, CH; R1 = H, alkyl, alkoxy, halo, aminoalkyl, NO2; R2 = H, NR4COAr, NR4Ar, SCH2Ar, etc.; Ar = (substituted) naphthyl, Ph; R3 = H, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl; R4 = H, alkyl; R5 = H, alkyl, alkoxy, Cl, F, OH, dialkylamino, CF3, OCF3; with provisos], were prepared Thus, 10-[4-[[(2-biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine hydrochloride, prepared in several steps starting from isatoic anhydride and pipecolic acid, bound to vasopressin V2 receptors with IC50 = 9 nM.

IT **285559-00-4P 285559-01-5P 285559-02-6P**
285559-03-7P 285559-04-8P 285559-05-9P
285559-06-0P 285559-07-1P 285559-08-2P
285559-09-3P 285559-10-6P 285559-11-7P
285559-12-8P 285559-13-9P 285559-14-0P
285559-15-1P 285559-16-2P 285559-17-3P
285559-18-4P 285559-19-5P 285559-20-8P
285559-21-9P 285559-22-0P 285559-23-1P
285559-24-2P 285559-25-3P 285559-26-4P
285559-27-5P 285559-28-6P 285559-29-7P
285559-30-0P 285559-31-1P 285559-32-2P
285559-33-3P 285559-34-4P 285559-35-5P
285559-36-6P 285559-37-7P 285559-38-8P
285559-39-9P 285559-40-2P 285559-41-3P
285559-42-4P 285559-43-5P 285559-44-6P
285559-45-7P 285559-46-8P 285559-47-9P
285559-48-0P 285559-49-1P 285559-50-4P
285559-52-6P 285559-53-7P 285559-55-9P
285559-56-0P 285559-57-1P 285559-59-3P
285559-60-6P 285559-61-7P 285559-62-8P
285559-63-9P 285559-64-0P 285559-65-1P
285559-66-2P 285559-67-3P 285559-68-4P
285559-69-5P 285559-70-8P 285559-84-4P
285559-85-5P 285559-86-6P 285559-87-7P
285559-88-8P 285559-89-9P 285559-90-2P
285559-91-3P 285559-92-4P 285559-93-5P
285559-94-6P 285559-95-7P 285559-96-8P
285559-97-9P 285559-98-0P 285559-99-1P
285560-00-1P 285560-01-2P 285560-02-3P
285560-03-4P 285560-04-5P 285560-05-6P
285560-06-7P 285571-93-9P 444162-28-1P
444162-30-5P 444162-32-7P 444162-34-9P
444162-36-1P 444162-38-3P 444162-40-7P
444162-42-9P 444162-44-1P 444162-46-3P
444162-48-5P 444162-50-9P 444162-52-1P
444162-54-3P 444162-55-4P 444162-56-5P
444162-57-6P 444162-59-8P 444162-61-2P
444162-63-4P 444162-65-6P 444162-67-8P
444162-69-0P 444162-71-4P 444162-73-6P
444162-75-8P 444162-77-0P 444162-79-2P
444162-81-6P 444162-83-8P 444162-85-0P
444162-87-2P 444162-89-4P 444162-91-8P
444162-93-0P 444162-95-2P 444162-97-4P
444162-99-6P 444163-01-3P 444163-03-5P
444163-05-7P 444163-07-9P 444163-09-1P
444163-11-5P 444163-13-7P 444163-15-9P
444163-17-1P 444163-19-3P 444163-21-7P
444163-23-9P 444163-25-1P 444163-27-3P
444163-29-5P 444163-31-9P 444163-33-1P
444163-35-3P 444163-37-5P 444163-39-7P
444163-41-1P 444163-43-3P 444163-45-5P
444163-47-7P 444163-48-8P 444163-49-9P
444163-50-2P 444163-51-3P 444163-53-5P
444163-56-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzodiazepines as vasopressin receptor

antagonists)
RN 285559-00-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,8,9,10-hexahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-01-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,10-tetrahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-02-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-

[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-03-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 285559-04-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4'-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 285559-05-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4'-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-04-8
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-06-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-07-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-5-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-06-0
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-08-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-3'-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-09-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-3'-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-08-2
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-10-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-11-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-10-6
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-12-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro-2-(5-methyl-3-thienyl)- (9CI) (CA INDEX NAME)



RN 285559-13-9 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro-2-(5-methyl-3-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-12-8
CMF C31 H27 Cl F N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-14-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 285559-15-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-14-0
CMF C28 H28 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-16-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 285559-17-3 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-16-2
CMF C28 H28 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-18-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-19-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-18-4
CMF C33 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-20-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aR)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 285559-21-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-22-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-23-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3,4,5-tetrafluoro- (9CI) (CA INDEX NAME)



RN 285559-24-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3,4,5-tetrafluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-23-1
CMF C26 H20 Cl F4 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-25-3 CAPLUS
CN Benzamide, 2-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 285559-26-4 CAPLUS
CN Benzamide, 2-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-25-3
CMF C27 H22 Cl2 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-27-5 CAPLUS
CN Benzamide, 3-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 285559-28-6 CAPLUS
CN Benzamide, 3-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-27-5
CMF C26 H22 Cl2 F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-29-7 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-[(difluoromethyl)thio]-(9CI) (CA INDEX NAME)



RN 285559-30-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-[(difluoromethyl)thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-29-7
CMF C27 H24 Cl F2 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-31-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-32-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-31-1
CMF C32 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-33-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-5-oxido-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-34-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-5-oxido-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-33-3
CMF C32 H28 Cl N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-35-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-36-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-37-7 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 285559-38-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-37-7
CMF C27 H26 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-39-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 285559-40-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-39-9
CMF C33 H30 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-41-3 CAPLUS
CN Benzamide, 2-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-42-4 CAPLUS
CN Benzamide, 2-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-41-3
CMF C27 H27 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-43-5 CAPLUS
CN Benzamide, 2-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-44-6 CAPLUS
CN Benzamide, 2-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-43-5
CMF C28 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-45-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-46-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-45-7
CMF C34 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-47-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-48-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-47-9
CMF C33 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-49-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 285559-50-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-49-1
CMF C33 H30 F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-52-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-53-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-55-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8,9-dimethoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-56-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(9-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-57-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8,9-difluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-59-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-60-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-61-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-62-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-63-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-64-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-65-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-iodo-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-66-2 CAPLUS
CN Benzamide, 3,5-dichloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-67-3 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3-iodo-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-68-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-fluoro-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-69-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(dimethylamino)-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 285559-70-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 285559-84-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,8,9,10-hexahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-85-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aR)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 285559-86-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-87-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-88-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-89-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-90-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-91-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-92-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8,9-dimethoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-93-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(9-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-94-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8,9-difluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-95-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-96-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-97-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-98-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-99-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-00-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 285560-01-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-iodo-3-methyl- (9CI) (CA INDEX NAME)



RN 285560-02-3 CAPLUS
CN Benzamide, 3,5-dichloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-03-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3-iodo-2-methyl- (9CI) (CA INDEX NAME)



RN 285560-04-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-fluoro-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-05-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(dimethylamino)-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285560-06-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285571-93-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 444162-28-1 CAPLUS
CN Benzamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 444162-30-5 CAPLUS
CN Benzamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 444162-32-7 CAPLUS
CN Benzamide, N-[2-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 444162-34-9 CAPLUS
CN Benzamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 444162-36-1 CAPLUS
CN Benzamide, 2-(4-methyl-2-thienyl)-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-38-3 CAPLUS
CN Benzamide, 2-(4-methyl-2-thienyl)-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-40-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-2,2-dioxido-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-42-9 CAPLUS
CN Benzamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 444162-44-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 444162-46-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)



RN 444162-48-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-50-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-52-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-54-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-55-4 CAPLUS
CN Benzamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 444162-56-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 444162-57-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 444162-59-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3'-methoxy- (9CI) (CA INDEX NAME)



RN 444162-61-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)



RN 444162-63-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-methoxy- (9CI) (CA INDEX NAME)



RN 444162-65-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 444162-67-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-69-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[[1,2,3,4,12,12a-hexahydro-2-(phenylmethyl)pyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-71-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydropyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-73-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(2-formyl-1,2,3,4,12,12a-hexahydropyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-75-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[[1,2,3,4,12,12a-hexahydro-2-(1-methylethyl)pyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-77-0 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444162-79-2 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 444162-81-6 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 444162-83-8 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 444162-85-0 CAPLUS
CN Benzamide, 3-chloro-N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 444162-87-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444162-89-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 444162-91-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3'-methoxy- (9CI) (CA INDEX NAME)



RN 444162-93-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-95-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-fluoro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444162-97-4 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methoxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444162-99-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 444163-01-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methoxyphenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444163-03-5 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-(trifluoromethyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-05-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 444163-07-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-(trifluoromethyl)phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444163-09-1 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methylphenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-11-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methylphenyl]- (9CI) (CA INDEX NAME)



RN 444163-13-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3-methylphenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444163-15-9 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3,5-dimethylphenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-17-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 444163-19-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-3,5-dimethylphenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444163-21-7 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-methoxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-23-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 444163-25-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-methoxyphenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 444163-27-3 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-29-5 CAPLUS
CN Benzamide, N-[2-fluoro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-31-9 CAPLUS
CN Benzamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-methylphenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-33-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 444163-35-3 CAPLUS
CN Benzamide, N-[2-chloro-4-[[1,2,3,4,12,12a-hexahydro-2-(2,2,2-trifluoroethyl)pyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-37-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[[1,2,3,4,12,12a-hexahydro-2-(2,2,2-trifluoroethyl)pyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444163-39-7 CAPLUS
CN Benzamide, 2-chloro-N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444163-41-1 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3,4,5-tetrafluoro- (9CI) (CA INDEX NAME)



RN 444163-43-3 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-45-5 CAPLUS
CN Benzamide, 3-chloro-N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 444163-47-7 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro-5-methyl- (9CI) (CA INDEX NAME)



RN 444163-48-8 CAPLUS
CN Benzamide, 2,3-dichloro-N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444163-49-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444163-50-2 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 444163-51-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 444163-53-5 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 444163-56-8 CAPLUS
CN Benzamide, N-[2-chloro-4-[(1,2,3,4,12,12a-hexahydro-2-methylpyrazino[2,1-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3-fluoro-2-methyl- (9CI) (CA INDEX NAME)



IT **285559-73-1P 285559-74-2P 285559-80-0P**
285559-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic benzodiazepines as vasopressin receptor antagonists)

RN 285559-73-1 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5,6,6a,7,8,9,10,12-octahydro-5-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)



RN 285559-74-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-(4-aminobenzoyl)-5,6,6a,7,8,9,10,12-octahydro- (9CI) (CA INDEX NAME)



RN 285559-80-0 CAPLUS
CN 1H-[1,4]Oxazino[3,4-c][1,4]benzodiazepine, 11-(2-chloro-4-nitrobenzoyl)-3,4,6,11,12,12a-hexahydro-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285559-81-1 CAPLUS
CN 1H-[1,4]Oxazino[3,4-c][1,4]benzodiazepine, 11-(4-amino-2-chlorobenzoyl)-3,4,6,11,12,12a-hexahydro-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NH2
Cl
H
N
O
O
S
N

L19 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:504647 CAPLUS
DOCUMENT NUMBER: 137:83636
TITLE: Combination drugs containing NK-1 receptor antagonists and NK-2 receptor antagonists and/or cholinolytics
INVENTOR(S): Doi, Takayuki; Hashimoto, Tadatoshi; Kamo, Izumi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051440	A1	20020704	WO 2001-JP11231	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432543	AA	20020704	CA 2001-2432543	20011221
JP 2002249432	A2	20020906	JP 2001-390486	20011221
EP 1352659	A1	20031015	EP 2001-271853	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004058914	A1	20040325	US 2003-451431	20030623
PRIORITY APPLN. INFO.:			JP 2000-391013 A	20001222
			WO 2001-JP11231 W	20011221

OTHER SOURCE(S): MARPAT 137:83636
GI



I

AB Disclosed are drugs useful as preventives and remedies for urinary frequency, urinary incontinence, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, arthritis deformans, pain, cough, irritable bowel syndrome, vomiting, depression, anxiety, manic-depression or schizophrenia which comprise a combination of an NK-1 receptor antagonist and an NK-2 receptor antagonist and/or a cholinolytic. More specifically,

drugs comprising a combination of a compound represented by the following formula I [wherein the ring M represents a heterocycle having, as the partial structure -X-Y< thereof, -N=C<, -CO-N< or -CS-N<; Ra and Rb are bonded to each other to form the ring A, or Ra and Rb may be the same or different and each represents hydrogen or a substituent in the ring M; the rings A and B are each an optionally substituted homocycle or heterocycle and at least one of them is an optionally substituted heterocycle; the ring C is an optionally substituted homocycle or heterocycle; the ring Z is an optionally substituted nitrogen-containing heterocycle; and n is an integer of 1 to 6], its salt or a prodrug thereof with an NK-2 receptor antagonist and/or a cholinolytic. The effect of (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-g][1,7] naphthyridine and (±)SR48968 (saredutant) hydrochloride in cyclophosphamide-induced urinary frequency rats were examined

IT **404867-31-8 439696-15-8**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination drugs containing NK-1 receptor antagonists and NK-2 receptor antagonists and/or cholinolytics)

RN 404867-31-8 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-4-methyl-12-(4-methylphenyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439696-15-8 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-4-methyl-12-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:465810 CAPLUS
DOCUMENT NUMBER: 137:46797
TITLE: Diarylsulfonamides and N-arylbenzamides as nonpeptide agonists and antagonists of vasopressin receptors
INVENTOR(S): Snyder, James P.; Liotta, Dennis C.; Venkatesan, Hariharan; Wang, Minmin; Davis, Matthew C.
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047679	A2	20020620	WO 2001-US49303	20011217
WO 2002047679	C1	20030130		
WO 2002047679	A3	20030612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432825	AA	20020620	CA 2001-2432825	20011217
AU 2002031098	A5	20020624	AU 2002-31098	20011217
US 2002128208	A1	20020912	US 2001-23603	20011217
PRIORITY APPLN. INFO.:			US 2000-255946P P	20001215
			WO 2001-US49303 W	20011217

OTHER SOURCE(S): MARPAT 137:46797
GI



I

AB The title compds. were prepared as agonists and/or antagonists of V2, V1a or both receptors, in humans, for use in treating renal dysfunction or hypertension (no data). Thus, the sulfonamide I was obtained by

benzoylating p-phenylenediamine and reaction with (-)-camphorsulfonyl chloride.

IT **438192-55-3P 438192-56-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(diarylsulfonamides and N-arylbenzamides as nonpeptide agonists and antagonists of vasopressin receptors)

RN 438192-55-3 CAPLUS

CN Pyrido[2,1-c][1,4]benzodiazepin-6(6aH)-one, 5,7,8,9,10,12-hexahydro-5-[(2-methoxy-4-nitrophenyl)methyl]-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438192-56-4 CAPLUS

CN Pyrido[2,1-c][1,4]benzodiazepin-6(6aH)-one, 5-[(4-amino-2-methoxyphenyl)methyl]-5,7,8,9,10,12-hexahydro-, (6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **438192-53-1P 438192-54-2P 438192-57-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(diarylsulfonamides and N-arylbenzamides as nonpeptide agonists and antagonists of vasopressin receptors)

RN 438192-53-1 CAPLUS

CN Benzamide, 4-[[(6aS)-6,6a,7,8,9,10-hexahydro-6-oxopyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438192-54-2 CAPLUS
CN Benzamide, N-[1,1'-biphenyl]-2-yl-4-[[(6aS)-6,6a,7,8,9,10-hexahydro-6-oxopyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438192-57-5 CAPLUS
CN Benzenesulfonamide, N-[4-[[(6aS)-6,6a,7,8,9,10-hexahydro-6-oxopyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl]methyl]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


O
O
S
HN
Ph
MeO
O
H
N
S
N

L19 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:220552 CAPLUS
DOCUMENT NUMBER: 136:247613
TITLE: Preparation of tricyclic heterocyclic compounds as tachykinin receptor antagonists
INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Tarui, Naoki; Kamo, Izumi; Shirai, Junya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022574	A1	20020321	WO 2001-JP7815	20010910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086188	A5	20020326	AU 2001-86188	20010910
JP 2002155084	A2	20020528	JP 2001-274336	20010910
PRIORITY APPLN. INFO.:			JP 2000-280154 A	20000911
			WO 2001-JP7815 W	20010910

OTHER SOURCE(S): MARPAT 136:247613
GI



I

AB The title compds. I [A = (CH2)n ; R represents hydrogen, halo, etc.; R1 represents hydrogen, optionally substituted alkyl, aryl, acyl, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl, or alkylsulfonyl; R2 represents hydrogen, halogeno, or optionally halogenated alkyl; R3 represents hydrogen or alkyl; R represents hydrogen, halogeno, optionally halogenated alkyl, or optionally halogenated alkoxy; m is an integer of 0

to 3; n is 1 or 2; and p is an integer of 0 to 3; a proviso is given] are prepared I are useful in the treatment of urination disorder. Processes for preparing I are claimed. In an in vitro test for substance P antagonism, compds. of this invention showed IC50 of 0.0164 nM to 0.0762 nM. Formulations are given.

IT **404867-03-4P 404867-05-6P 404867-06-7P**
404867-07-8P 404867-08-9P 404867-09-0P
404867-10-3P 404867-11-4P 404867-12-5P
404867-13-6P 404867-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic heterocyclic compds. as tachykinin receptor antagonists)

RN 404867-03-4 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethoxyphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-9-methyl- (9CI) (CA INDEX NAME)



RN 404867-05-6 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethoxyphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4,9-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-06-7 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-07-8 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4-methyl-, monohydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-08-9 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4,9-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-09-0 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-ethyl-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-10-3 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4-methyl-9-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-11-4 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 9-acetyl-2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-12-5 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethylphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5,8,9,10,11-octahydro-4,9-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-13-6 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5,8,9,10,11-octahydro-9-methyl-12-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 404867-14-7 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5,8,9,10,11-octahydro-4,9-dimethyl-12-(4-methylphenyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **404867-15-8P 404867-21-6P 404867-23-8P**
404867-26-1P 404867-29-4P 404867-31-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic heterocyclic compds. as tachykinin receptor antagonists)

RN 404867-15-8 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethoxyphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 404867-21-6 CAPLUS

CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethoxyphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5-tetrahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-23-8 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-12-(4-fluorophenyl)-2,3,4,5-tetrahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-26-1 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[(3,5-dimethylphenyl)methyl]-12-(4-fluorophenyl)-2,3,4,5-tetrahydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404867-29-4 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-12-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 404867-31-8 CAPLUS
CN [1,4]Diazepino[1,2-b][2,7]naphthyridine-1,7-dione, 2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-4-methyl-12-(4-methylphenyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

grandparent

L19 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:513702 CAPLUS
DOCUMENT NUMBER: 133:120350
TITLE: Preparation of tricyclic benzodiazepines as vasopressin receptor antagonists
INVENTOR(S): Hoekstra, William J.; Dyatkin, Alexey B.; Maryanoff, Bruce E.; Matthews, Jay M.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043398	A2	20000727	WO 1999-US30423	19991221
WO 2000043398	A3	20010111		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2360767	AA	20000727	CA 1999-2360767	19991221
EP 1147115	A2	20011024	EP 1999-966495	19991221
EP 1147115	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9917086	A	20011030	BR 1999-17086	19991221
TR 200102069	T2	20011121	TR 2001-200102069	19991221
AT 249465	E	20030915	AT 1999-966495	19991221
NZ 512960	A	20040130	NZ 1999-512960	19991221
PT 1147115	T	20040227	PT 1999-966495	19991221
AU 772397	B2	20040429	AU 2000-22014	19991221
ES 2207333	T3	20040516	ES 1999-966495	19991221
RU 2250899	C2	20050427	RU 2001-123247	19991221
NO 2001003515	A	20010917	NO 2001-3515	20010716
HK 1038361	A1	20040507	HK 2002-100064	20020104
PRIORITY APPLN. INFO.:			US 1999-116358P P	19990119
			US 1999-468650 A	19991221
			WO 1999-US30423 W	19991221

OTHER SOURCE(S): MARPAT 133:120350
GI



I

AB Title compds. [I; A = CO, SO2, CH2; Y = CH2, CH; X = CH2, CH, NR3, S, O; Z = N, CH; R1 = H, alkyl, alkoxy, halo, aminoalkyl, NO2; R2 = H, NR4COAr, NR4Ar, SCH2Ar, etc.; Ar = (substituted) naphthyl, Ph; R3 = H, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl; R4 = H, alkyl; R5 = H, alkyl, alkoxy, Cl, F, OH, dialkylamino, CF3, OCF3; Q = atoms to form a benzene or 5-6 membered heterocyclic ring; with provisos], were prepared Thus, 10-[4-[[(2-biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine hydrochloride, prepared in several steps starting from isatoic anhydride and pipecolic acid, bound to vasopressin V2 receptors with IC50 = 9 nM.

IT **285559-00-4P 285559-01-5P 285559-02-6P**
285559-03-7P 285559-04-8P 285559-05-9P
285559-06-0P 285559-07-1P 285559-08-2P
285559-09-3P 285559-10-6P 285559-11-7P
285559-12-8P 285559-13-9P 285559-14-0P
285559-15-1P 285559-16-2P 285559-17-3P
285559-18-4P 285559-19-5P 285559-20-8P
285559-21-9P 285559-22-0P 285559-23-1P
285559-24-2P 285559-25-3P 285559-26-4P
285559-27-5P 285559-28-6P 285559-29-7P
285559-30-0P 285559-31-1P 285559-32-2P
285559-33-3P 285559-34-4P 285559-35-5P
285559-36-6P 285559-37-7P 285559-38-8P
285559-39-9P 285559-40-2P 285559-41-3P
285559-42-4P 285559-43-5P 285559-44-6P
285559-45-7P 285559-46-8P 285559-47-9P
285559-48-0P 285559-49-1P 285559-50-4P
285559-52-6P 285559-53-7P 285559-55-9P
285559-56-0P 285559-57-1P 285559-59-3P
285559-60-6P 285559-61-7P 285559-62-8P
285559-63-9P 285559-64-0P 285559-65-1P
285559-66-2P 285559-67-3P 285559-68-4P
285559-69-5P 285559-70-8P 285559-84-4P
285559-85-5P 285559-86-6P 285559-87-7P
285559-88-8P 285559-89-9P 285559-90-2P
285559-91-3P 285559-92-4P 285559-93-5P
285559-94-6P 285559-95-7P 285559-96-8P
285559-97-9P 285559-98-0P 285559-99-1P
285560-00-1P 285560-01-2P 285560-02-3P
285560-03-4P 285560-04-5P 285560-05-6P
285560-06-7P 285571-93-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic benzodiazepines as vasopressin receptor antagonists)

RN 285559-00-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,8,9,10-hexahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-01-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,10-tetrahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-02-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-03-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 285559-04-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4'-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 285559-05-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4'-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-04-8
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-06-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-

yl]carbonyl]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-07-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-5-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-06-0
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-08-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-3'-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-09-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-3'-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-08-2
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-10-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285559-11-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-4-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-10-6
CMF C32 H28 Cl N3 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-12-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro-2-(5-methyl-3-thienyl)- (9CI) (CA INDEX NAME)



RN 285559-13-9 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4-fluoro-2-(5-methyl-3-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-12-8
CMF C31 H27 Cl F N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-14-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 285559-15-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,6-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-14-0
CMF C28 H28 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-16-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 285559-17-3 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-16-2
CMF C28 H28 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-18-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-19-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-18-4
CMF C33 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-20-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aR)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 285559-21-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-22-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-23-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3,4,5-tetrafluoro- (9CI) (CA INDEX NAME)



RN 285559-24-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2,3,4,5-tetrafluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-23-1
CMF C26 H20 Cl F4 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-25-3 CAPLUS
CN Benzamide, 2-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 285559-26-4 CAPLUS
CN Benzamide, 2-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-25-3
CMF C27 H22 Cl2 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-27-5 CAPLUS
CN Benzamide, 3-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 285559-28-6 CAPLUS
CN Benzamide, 3-chloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-27-5
CMF C26 H22 Cl2 F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-29-7 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-[(difluoromethyl)thio]-(9CI) (CA INDEX NAME)



RN 285559-30-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-[(difluoromethyl)thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-29-7
CMF C27 H24 Cl F2 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-31-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-32-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-31-1
CMF C32 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-33-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-5-oxido-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-34-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-5-oxido-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-33-3
CMF C32 H28 Cl N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-35-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-36-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-37-7 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 285559-38-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-37-7
CMF C27 H26 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-39-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 285559-40-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-39-9
CMF C33 H30 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-41-3 CAPLUS
CN Benzamide, 2-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-42-4 CAPLUS
CN Benzamide, 2-methyl-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-41-3
CMF C27 H27 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-43-5 CAPLUS
CN Benzamide, 2-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-44-6 CAPLUS
CN Benzamide, 2-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-43-5
CMF C28 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-45-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-46-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 4'-methyl-N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-45-7
CMF C34 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-47-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-48-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methyl-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-47-9
CMF C33 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-49-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 285559-50-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-fluoro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-4'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 285559-49-1
CMF C33 H30 F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 285559-52-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-53-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-55-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8,9-dimethoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-56-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(9-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-57-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8,9-difluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-59-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-60-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-61-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 285559-62-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-63-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-64-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-65-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-iodo-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-66-2 CAPLUS
CN Benzamide, 3,5-dichloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-67-3 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3-iodo-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-68-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-fluoro-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 285559-69-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(dimethylamino)-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 285559-70-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 285559-84-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(6,6a,7,8,9,10-hexahydropyrido[2,1-c][1,4]benzodiazepin-5(12H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-85-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aR)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 285559-86-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-87-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-methoxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-88-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-89-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-hydroxy-4-[(3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-90-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-91-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-92-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8,9-dimethoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-93-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(9-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-94-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8,9-difluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-95-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-8-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-96-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(8-chloro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-97-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[(8-fluoro-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-98-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methyl-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285559-99-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[(3,4,12,12a-tetrahydro-10-methoxy-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-00-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 285560-01-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-2-iodo-3-methyl- (9CI) (CA INDEX NAME)



RN 285560-02-3 CAPLUS
CN Benzamide, 3,5-dichloro-N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-03-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]-3-iodo-2-methyl- (9CI) (CA INDEX NAME)



RN 285560-04-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-fluoro-N-[4-[(3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 285560-05-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(dimethylamino)-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285560-06-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 285571-93-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-chloro-4-[[(12aS)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzodiazepin-11(6H)-yl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **285559-73-1P 285559-74-2P 285559-80-0P**
285559-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic benzodiazepines as vasopressin receptor antagonists)

RN 285559-73-1 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5,6,6a,7,8,9,10,12-octahydro-5-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)



RN 285559-74-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-(4-aminobenzoyl)-5,6,6a,7,8,9,10,12-octahydro- (9CI) (CA INDEX NAME)



RN 285559-80-0 CAPLUS
CN 1H-[1,4]Oxazino[3,4-c][1,4]benzodiazepine, 11-(2-chloro-4-nitrobenzoyl)-3,4,6,11,12,12a-hexahydro-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285559-81-1 CAPLUS
CN 1H-[1,4]Oxazino[3,4-c][1,4]benzodiazepine, 11-(4-amino-2-chlorobenzoyl)-3,4,6,11,12,12a-hexahydro-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NH2
Cl
H
N
O
O
S
N

L19 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:383926 CAPLUS
DOCUMENT NUMBER: 133:17490
TITLE: Preparation of [1,4]diazepino[2,1-g][1,7]naphthyridine, [1,4]diazonino[2,1-g][1,7]naphthyridine, 13H-[1,4]diazocino[2,1-g][1,7]naphthyridine, and pyrido[3,2-f][1,4]oxazepine derivatives and related compounds as antiemetics
INVENTOR(S): Doi, Takayuki; Yamamoto, Masaki; Fukui, Hideo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032192	A1	20000608	WO 1999-JP6569	19991125
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2352612	AA	20000608	CA 1999-2352612	19991125
EP 1145714	A1	20011017	EP 1999-972920	19991125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000273042	A2	20001003	JP 1999-336187	19991126
PRIORITY APPLN. INFO.:			JP 1998-337438 A	19981127
			JP 1999-10907 A	19990119
			WO 1999-JP6569 W	19991125

OTHER SOURCE(S): MARPAT 133:17490
GI For diagram(s), see printed CA Issue.
AB Drugs comprising compds. represented by general formula (I) (wherein the ring M is a heterocycle having, as the partial structure X:Y, N:C, CO-N or CS-N; Ra and Rb are bonded to each other to form the ring A, or Ra and Rb are the same or different and each represents hydrogen or a substituent of the ring M; the rings A and B are each an optionally substituted homocyclic or heterocycle and at least one of them is an optionally substituted heterocycle; the ring C is an optionally substituted homocyclic or heterocycle; the ring Z is an optionally substituted nitrogen-containing heterocycle; and n is an integer of 1 to 6) or salts thereof combined with emetic drugs are claimed. The compds. I or salts thereof are useful as antiemetic agents which, in particular, can rapidly and safely inhibit even at a small dose emesis induced by emetic drugs such as anticancer agents, morphine, and apomorphine. Thus, a mixture of (R)-N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxy-3-methylbutyl)-5-(4-methylphenyl)-8-oxo-6-pyrido[3,4-b]pyridinecarboxamide (preparation given), Et3N, and MeSO2Cl in THF was stirred at room temperature for 30 min, followed by treatment of the product with NaH in THF at room temperature for 1.5 h to give (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-

g][1,7]naphthyridine (II). II at 1-10 mg/kg p.o. in vivo inhibited cisplatin-induced emesis in male ferret. Pharmaceutical formulations containing I were prepared

IT **183549-77-1P 183549-79-3P 183549-82-8P**
183549-87-3P 183549-88-4P 183549-89-5P
183550-02-9P 183550-03-0P 183550-08-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 13H-[1,4]diazocino[g][1,7]naphthyridine derivs. and related compds. as antiemetics)

RN 183549-77-1 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183549-79-3 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-7-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183549-82-8 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 183549-87-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183549-88-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183549-89-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183550-02-9 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-hydroxy-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183550-03-0 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-5-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183550-08-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,4-dichlorophenyl)methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:613656 CAPLUS
DOCUMENT NUMBER: 131:228734
TITLE: Preparation of diazocinonaphthyridines, diazepinonaphthyridines, and related compounds having tachykinin receptor antagonistic activity for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.
INVENTOR(S): Natsugari, Hideaki; Doi, Takayuki; Ikeura, Yoshinori
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947132	A2	19990923	WO 1999-JP1358	19990318
WO 9947132	A3	19991111		
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321155	AA	19990923	CA 1999-2321155	19990318
AU 9928532	A1	19991011	AU 1999-28532	19990318
AU 751114	B2	20020808		
JP 11322748	A2	19991124	JP 1999-72954	19990318
BR 9908895	A	20001205	BR 1999-8895	19990318
EP 1061926	A2	20001227	EP 1999-909233	19990318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1184036	A2	20020306	EP 2001-127194	19990318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 2000004144	A	20001010	NO 2000-4144	20000818
US 2002132817	A1	20020919	US 2002-97791	20020313

PRIORITY APPLN. INFO.:

JP 1998-69999	A	19980319
EP 1999-909233	A3	19990318
WO 1999-JP1358	W	19990318
US 1999-308311	A1	19990518

OTHER SOURCE(S): MARPAT 131:228734
GI



I

AB Pharmaceutical compns. for preventing or treating depression, anxiety, manic-depression, or psychopathy [I; XY = N:C, CON, CSN; Ra, Rb = H, substituent; RaRb = atoms to form a (substituted) (heterocyclic) ring; B, E = (substituted) homocyclic or heterocyclic ring, Z = (substituted) N-containing heterocyclic ring; n = 1-6; with provisos], are claimed. Thus, (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]-diazocino[2,1-g][1,7]naphthyridine (II) (preparation described) antagonized substance P with IC50 = 0.43 nM. A II tablet formulation is given.

IT **183549-77-1P 183549-79-3P 183549-82-8P**
183549-87-3P 183549-88-4P 183549-89-5P
183550-02-9P 183550-03-0P 183550-08-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazocinonaphthyridines, diazepinonaphthyridines, and related compds. having tachykinin receptor antagonistic activity)

RN 183549-77-1 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183549-79-3 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-7-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183549-82-8 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 183549-87-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183549-88-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183549-89-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183550-02-9 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-hydroxy-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183550-03-0 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-5-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183550-08-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,4-dichlorophenyl)methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



L19 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:567004 CAPLUS
DOCUMENT NUMBER: 131:337008
TITLE: Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions
AUTHOR(S): Natsugari, Hideaki; Ikeura, Yoshinori; Kamo, Izumi; Ishimaru, Takenori; Ishichi, Yuji; Fujishima, Akira; Tanaka, Toshimasa; Kasahara, Fumiko; Kawada, Mitsuru; Doi, Takayuki
CORPORATE SOURCE: Pharmaceutical Research Division and Technology Development Department, Takeda Chemical Industries Ltd., Yodogawa-ku Osaka, 532-8686, Japan
SOURCE: Journal of Medicinal Chemistry (1999), 42(19), 3982-3993
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Cyclic analogs of N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide having a 6-9-membered ring I and II [X = (CH2)n, n = 2-5; X = (R)-, (S)-CH2CHMeCH2, (R)-, (S)-(CH2)2CHMECH2] were synthesized and evaluated for NK1 antagonistic activities. The 8-membered ring compound with a β-Me group at the C(9)-position, (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-Me -5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dion e [(aR,9R)-III], was atropdiastereoselectively synthesized by cyclization of a chiral carboxamide intermediate, IV [X = (R)-(CH2)2CHMeCH2]. On the other hand, the 7-membered ring compound with a β-Me group at the C(9)-position [(9S)-II (n = 3)] was obtained as an equilibrium mixture of atropisomers with a ratio of ca. 3:2 in solution at room temperature (measured by NMR in CDCl3). Compds. (9S)-II (n = 3) and (aR,9R)-III exhibited excellent antagonistic activities both in vitro [IC50 (inhibition of [125I]BH-SP binding in human IM-9 cells) = 0.28 and 0.45 nM, resp.] and in vivo (iv and po). Significantly, the in vitro activity of (aR,9R)-III was ca. 750-fold higher than that of its enantiomer (aS,9S)-III, ca. 40-fold higher than its atropisomer (aS,9R)-III, and ca. 20-fold higher than its diastereomer (aR,9S)-III. The structure-activity relationships in this series, along with the X-ray anal. of (aR,9R)-III, indicated that the stereochem. around the -C(6)(:O)-N(7)-CH2Ar moiety is important for NK1 receptor recognition. The NK1 antagonists showed effects on bladder functions in guinea pigs upon i.v. injection: i.e., the antagonists increased the shutdown time of distension-induced rhythmic bladder contractions and the bladder volume threshold, and the effects on the shutdown time were found to correlate well with the NK1 antagonistic activities. Compound (aR,9R)-III has been identified as a potential clin. candidate for the treatment of bladder function disorders.
IT **183549-77-1P 183549-87-3P 183549-89-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, NK1 receptor antagonist activity, crystal structure, and structure-activity relationship of naphthyridinecarboxamide derivs.)
RN 183549-77-1 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-

bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-(4-methylphenyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183549-87-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-
bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-
methylphenyl)-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183549-89-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:427772 CAPLUS
DOCUMENT NUMBER: 129:95515
TITLE: Preparation of medium-ring polycyclic heterocycles as tachykinin receptor antagonists
INVENTOR(S): Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Ikeura, Yoshinori; Kimura, Chiharu; Tarui, Naoki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 621,360.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5770590	A	19980623	US 1996-717801	19960923
JP 09263585	A2	19971007	JP 1996-66337	19960322
JP 2976097	B2	19991110		
JP 09263587	A2	19971007	JP 1997-20386	19960322
CN 1140172	A	19970115	CN 1996-106081	19960323
US 5786352	A	19980728	US 1996-621360	19960325
SG 69968	A1	20000125	SG 1996-6546	19960325
US 6147071	A	20001114	US 1998-87894	19980601
US 6489315	B1	20021203	US 2000-644306	20000823

PRIORITY APPLN. INFO.:

JP 1995-91436	A	19950324
JP 1995-207553	A	19950720
JP 1995-264727	A	19950918
JP 1996-30033	A	19960123
JP 1996-66337	A	19960322
US 1996-621360	A2	19960325
JP 1996-214698	A	19960814
US 1998-87894	A3	19980601

OTHER SOURCE(S): MARPAT 129:95515
GI



I



II

AB A variety of polycyclic heterocycles are disclosed, and in particular the compds. I and salts are claimed [wherein X = O, S; Ar1, Ar2 = certain (un)substituted Ph; m, n = 0 to 4; (m+n) = 2 to 4; p = 1 to 6]. The compds. show an excellent tachykinin receptor antagonistic effect. For instance, (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-g][1,7]naphthyridine, i.e., II [Y = absent, R = Me] (preparation given) underwent hydroxylation by Streptomyces subrutilus IFO 13388 to give II [Y = absent, R = CH2OH] (III). The latter underwent acetylation with Ac2O and pyridine, N-oxidation with m-ClC6H4C(O)OOH, and hydrolytic deacetylation, to give title compound II [Y = O, R = CH2OH]. III had an ID50 of 2.5 μg/kg i.v. for inhibiting capsaicin-induced tracheal plasma extravasation in anesthetized guinea pigs. I also showed substance P receptor antagonistic and NK2 receptor inhibitory activities.

IT **183549-77-1P 183549-79-3P 183549-82-8P**
183549-87-3P 183549-88-4P 183549-89-5P
183550-02-9P 183550-03-0P 183550-08-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of medium-ring polycyclic heterocycles as tachykinin receptor antagonists)

RN 183549-77-1 CAPLUS

CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-(4-methylphenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183549-79-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-7-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183549-82-8 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 183549-87-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183549-88-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183549-89-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183550-02-9 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-hydroxy-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183550-03-0 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-5-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183550-08-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,4-dichlorophenyl)methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:728630 CAPLUS
DOCUMENT NUMBER: 126:8145
TITLE: Preparation of polycyclic heterocycles as tachykinin receptor antagonists
INVENTOR(S): Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Ikeura, Yoshinori; Kimura, Chiharu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733632	A1	19960925	EP 1996-104500	19960321
EP 733632	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
NO 9601160	A	19960925	NO 1996-1160	19960321
NO 309272	B1	20010108		
TW 394773	B	20000621	TW 1996-85103427	19960321
AT 242243	E	20030615	AT 1996-104500	19960321
ES 2194937	T3	20031201	ES 1996-104500	19960321
CA 2172421	AA	19960925	CA 1996-2172421	19960322
AU 9648261	A1	19961003	AU 1996-48261	19960322
AU 699611	B2	19981210		
CN 1140172	A	19970115	CN 1996-106081	19960323
IL 117631	A1	20001121	IL 1996-117631	19960324
BR 9601125	A	19980106	BR 1996-1125	19960325
SG 69968	A1	20000125	SG 1996-6546	19960325
US 6489315	B1	20021203	US 2000-644306	20000823
PRIORITY APPLN. INFO.:			JP 1995-91436 A	19950324
			JP 1995-207553 A	19950720
			JP 1995-264727 A	19950918
			JP 1996-30033 A	19960123
			US 1996-621360 A3	19960325
			US 1998-87894 A3	19980601

OTHER SOURCE(S): MARPAT 126:8145
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; R = (CH2)nR4; R1,R2 = H or a substituent; R1R2 = atoms to complete a (hetero)cyclic ring; ring B = heterocyclic ring; R3,R4 = (hetero)cyclic ring; X-Y = N:C, C(O)N, C(S)N; n = 1-6] were prepared Thus, 4-BrC6H4Me was condensed with 2,3-pyridinedicarboxylic acid and the product amidated by HN(CH2CN)2 to give, after cyclization in 5 addnl. steps, 7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9-tetrahydro-5-(4-methylphenyl)-6,11-dioxo-11H-pyrazino[2,1-g][1,7]naphthyridine. Data for in vitro biol. activity of selected I were given.
IT **183549-77-1P 183549-79-3P 183549-82-8P**
183549-87-3P 183549-88-4P 183549-89-5P
183550-02-9P 183550-03-0P 183550-08-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polycyclic heterocycles as tachykinin receptor antagonists)
RN 183549-77-1 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-

bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-(4-methylphenyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183549-79-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-7-
[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183549-82-8 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-
bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI)

(CA INDEX NAME)



RN 183549-87-3 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183549-88-4 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-phenyl-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183549-89-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183550-02-9 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-9-hydroxy-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 183550-03-0 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7,8,9,10-tetrahydro-5-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183550-08-5 CAPLUS
CN [1,4]Diazepino[2,1-g][1,7]naphthyridine-6,12-dione, 7-[(3,4-dichlorophenyl)methyl]-7,8,9,10-tetrahydro-5-phenyl- (9CI) (CA INDEX NAME)


O
N
N
N
O
CH2
Ph
Cl
Cl

L10 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:143388 CAPLUS
DOCUMENT NUMBER: 98:143388
TITLE: Seven-membered heterocyclics. Part 29. Synthesis of 1,2-annelated 1,4-benzodiazepines and 4,1-benzoxazepines
AUTHOR(S): Mueller, Werner; Stauss, Urs
CORPORATE SOURCE: Forschungsinst. Wander, Wander A.-G., Bern, CH-3001, Switz.
SOURCE: Helvetica Chimica Acta (1982), 65(7), 2118-32
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 98:143388
GI



I



II



III

AB 1,2-Annelated 1,4-benzodiazepines, e.g. I, and 4,1-benzoxazepines, e.g. II, were prepared via nucleophilic aromatic substitution of 2-substituted piperazines, piperidines or pyrrolidines with activated aryl halides. Thus, 2,5-F(O2N)C6H3CN was treated with Et 4-methyl-2-piperazinecarboxylate to give the piperazine III, which underwent reductive cyclization followed by deamination to give I.

IT **85147-25-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85147-25-7 CAPLUS
CN Pyrazino[1,2-a][1,4]benzodiazepine, 6-benzoyl-1,2,3,4,4a,5,6,7-octahydro-3-methyl- (9CI) (CA INDEX NAME)


Me
N
N
N
C— Ph
O

L19 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:405700 CAPLUS
DOCUMENT NUMBER: 85:5700
TITLE: Hexahydropyridobenzodiazepinones
INVENTOR(S): Kaemmerer, Friedrich J.; Perrey, Klaus
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2443567	A1	19760401	DE 1974-2443567	19740912
DE 2443567	B2	19790802		
DE 2443567	C3	19800410		

PRIORITY APPLN. INFO.: DE 1974-2443567 A 19740912
GI


I


II


III


IV

AB Pyridobenzodiazepinones I and II (R = H, C1-12 alkyl, phenyl, benzyl; R1 = H, Cl, OMe, Me; R2 = alkyl, alkenyl, substituted alkyl, 3,4,5-(MeO)3C6H2CO) (76 compds.), including I (R = R2 = H, R1 = Cl; R = CHMe2, R1 = R2 = H) and II (R = Et, Pr, CHMe2, Bu, CH2CHMe2, Ph, R1 = R2 = H; R = R1 = H, R2 = pyrrolidinocarbonylmethyl) were prepared by treating tetrahydroquinolines with RCH(CO2Et)2, reducing III with LiAlH4, and Schmidt reaction of IV. I and II are analgesics and inflammation inhibitors. Thus, II (R = CH2CHMe2, R1 = R2 = H) had oral ED50 in the phenylquinone writhing test and the carrageenin edema test of 2.0 and 0.3 mg/kg resp.

IT **59314-89-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59314-89-5 CAPLUS
CN 6H-Pyrido[1,2,3-ef]-1,5-benzodiazepin-2(1H)-one, 3,4,7,8-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


N
N
O
CH2
MeO
OMe
OMe

L19 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:458892 CAPLUS
DOCUMENT NUMBER: 83:58892
TITLE: Octahydropyrrodo[2,1-c][1,4]benzodiazepines
INVENTOR(S): Carabateas, Philip M.
PATENT ASSIGNEE(S): Sterling Drug Inc.
SOURCE: U.S., 13 pp. Division of U.S. 3,763,183 (CA 79: 146567t).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3860600	A	19750114	US 1973-327324	19730129
US 3763183	A	19731002	US 1972-270463	19720710
PRIORITY APPLN. INFO.:			US 1972-270463	A3 19720710
			US 1970-30315	A3 19700420

GI For diagram(s), see printed CA Issue.
AB The benzodiazepine derivs. I (R = H, Cl, NO2; R1 = H, EtCO, HCO, etc.; R2 = H, CO2Et; X = CH2, CH2CH2, CHOH, S, etc.) were prepared Thus, isatoic anhydride was treated with L-proline and the pyrrolobenzodiazepinedione reduced with LiAlH4 to give I (R = R1 = R2 = H, X = CH2), which with (EtCO)2O gave I (R1 = EtCO). I were analgesic at 10-100 mg/kg, antiinflammatory at 100 mg/kg, and depressant at 8-300 mg/kg.
IT **41994-21-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41994-21-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-benzoyl-5,6,6a,7,8,9,10,12-octahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L19 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:546567 CAPLUS
DOCUMENT NUMBER: 79:146567
TITLE: 1,2,3,10,11,11a-Hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepines
INVENTOR(S): Carabateas, Philip M.
PATENT ASSIGNEE(S): Sterling Drug Inc.
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3763183	A	19731002	US 1972-270463	19720710
US 3732212	A	19730508	US 1970-30315	19700420
US 3860600	A	19750114	US 1973-327324	19730129
PRIORITY APPLN. INFO.:			US 1970-30315	A3 19700420
			US 1972-270463	A3 19720710

GI For diagram(s), see printed CA Issue.

AB Analgesic antiinflammatory and central depressant heterocyclobenzodiazepines (I, R = H, alkyl, alkanoyl, benzoyl, R1 = H, halo, NO2, alkyl, alkoxy, benzyloxy; R2 = H, OH, CH2OH; X = CH2, CH2CH2, CH:CH, S, o-phenylene) (65 compds.) were prepared Thus isatoic anhydride and L-(-)-proline was heated in DMF for 3 hr to give the 5,11-dione of I (R-R2 = H, X = CH2). Reduction of the dione with LiAlH4 in THF gave I (R-R2 = H, X = CH2).

IT **41994-21-2P 50424-71-0P 50424-72-1P**
50424-74-3P 50424-75-4P 50702-95-9P
50702-96-0P 50702-97-1P 50702-98-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 41994-21-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-benzoyl-5,6,6a,7,8,9,10,12-octahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 50424-71-0 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5,6,6a,7,8,9,10,12-octahydro-3-methyl-5-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 50424-72-1 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 4-chloro-5,6,6a,7,8,9,10,12-octahydro-5-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 50424-74-3 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-(2-chloro-4-methoxy-6-methylbenzoyl)-5,6,6a,7,8,9,10,12-octahydro-3-methyl-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 50424-75-4 CAPLUS

CN Pyrido[2,1-c][1,4]benzodiazepine, 5-(1,3-benzodioxol-5-ylcarbonyl)-5,6,6a,7,8,9,10,12-octahydro-1-methoxy- (9CI) (CA INDEX NAME)



RN 50702-95-9 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 3-chloro-5,6,6a,7,8,9,10,12-octahydro-5-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)



RN 50702-96-0 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 1-fluoro-5,6,6a,7,8,9,10,12-octahydro-5-[4-(methylsulfinyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 50702-97-1 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5,6,6a,7,8,9,10,12-octahydro-4-methoxy-5-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 50702-98-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-(2-chlorobenzoyl)-5,6,6a,7,8,9,10,12-octahydro-4-methyl- (9CI) (CA INDEX NAME)


Cl
O
C
Me
N
N

L19 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:442570 CAPLUS
DOCUMENT NUMBER: 79:42570
TITLE: 1,2,3,10,11,11a-Hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones
INVENTOR(S): Carabateas, Philip M.
PATENT ASSIGNEE(S): Sterling Drug Inc.
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3732212	A	19730508	US 1970-30315	19700420
US 3763183	A	19731002	US 1972-270463	19720710
PRIORITY APPLN. INFO.:			US 1970-30315	A3 19700420

GI For diagram(s), see printed CA Issue.

AB About 15 benzodiazepinedione derivs. I (Z = (CH2)3, (CH2)4, CH2CH(OH)CH2, benzo, CH2SCH2, etc.; R = H, Cl, NO2) were prepared and converted to the benzodiazepines II (R1 = EtCO, Me, H, Bz, etc.). Thus, isatoic anhydride was treated with L-(-)-proline to give I (Z = (CH2)3, R = H), which was reduced with LiAlH4 to give II (Z = (CH3)3, R = R1 = H). II were analgesic antagonists at 10-100 mg/kg, antiinflammatory at 20-100 mg/kg, and reduced psychomotor activity in mice at 8-300 mg/kg.

IT **41994-21-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41994-21-2 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepine, 5-benzoyl-5,6,6a,7,8,9,10,12-octahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L19 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1967:403106 CAPLUS
DOCUMENT NUMBER: 67:3106
TITLE: Preparation of 11-substituted-1,2,3,11,12,12a-hexahydro-4H,6H-pyrido[2,1-c][1.4]benzodiazepin-12-ones
PATENT ASSIGNEE(S): Geigy, J. R., A.-G.
SOURCE: Neth. Appl., 19 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6608673		19661227	NL	
DE 1695080			DE	
FR 1484420			FR	
GB 1083278			GB	
US 3324116		19670606	US 1965-466439	19650623
US 3483187		19691209	US	19650623
PRIORITY APPLN. INFO.:			US	19650623

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) useful as analgetic, tranquilizing and local anesthetic agents, are prepared by reaction of I (R = H) (II) with a reactive ester of ROH, in the presence of an acid binding agent in an inert solvent. II are prepared from pipecolic esters and o-nitrobenzyl halides in solvents, in the presence of an excess acid-binding agent; the o-nitrobenzylpipecolic esters are reduced in the presence of Raney Ni, the esters are hydrolyzed and the o-aminobenzylpipecolic acids are submitted to a ring-closure with an inorg. acid. Thus, 8 g. PtO2 is added to a solution of 200 g. picolinic acid in 1625 ml. 5N HCl in a pressure vessel. The mixture is heated at 70° and shaken with 5 atmospheric H until 23.8 kg./cm.2 H is absorbed. The reactor is cooled to the ambient temperature and the catalyst separated to give pipecolic acid-HCl (m. 265-6°), 100 g. of which is dissolved in 1050 ml. absolute EtOH, and 25 ml. chlorosulfonic acid added. The mixture is refluxed 24 hrs., and the solvent evaporated in vacuo to give ethyl pipecolate, b14 93-5°, n24D 1.4550. To a solution of 31.4 g. of the ester and 32 g. K2CO3 in 200 ml. PhMe, a solution of 34.3 g. 2-O2NC6H4CH2Cl in 150 ml. PhMe is added dropwise with stirring. The mixture is refluxed 12 hrs., and cooled to give Et 1-(2-nitrobenzyl)pipecolate as a yellow oil, b0.35 150-2°, n23D 1.5266; a solution of 33 g. of the ester in 500 ml. EtOH is hydrogenated at 1 atmospheric and ambient temperature with Raney Ni to give Et 1-(2-aminobenzyl)pipecolate, b0.5 146-7°, n23D 1.5392. The ester is dissolved in 300 ml. HCl and refluxed 5 hrs. and the yellow solution cooled to give II (R1 = R2 = H), m. 182-3° (EtOH); HCl salt m. .apprx.250°. Similarly prepared are II (R1, R2, and m.p. given): H, 8-Cl (III), 224-5°; H, 9-MeO, 205-7°; H, 9-Me, 231-2°; H, 9-CF3, 185-6°; H, 9-Cl, 182-3°; 8, 9-(MeO)2, 203-4°; 8,9-Me2, 229-30°; 8,9-Cl2, 199-200°, 8,9-OCH2O, 265-6°. To a suspension of 6.27 g. III in 50 ml. Me2SO, 1.5 g. NaOEt is added, the mixture is stirred 30 min. at ambient temperature, and 5.3 g. MeI is added. The stirring is continued 1 hr., and the mixture added to 500 ml. cold H2O. The mixture is made alkaline (3N NaOH) and left overnight in a refrigerator to give I (R1 = H, R2 = 8-Cl, R = Me) (IV), m. 107-8° (C6H14)). An alternative

consists in stirring a solution of 10 g. III, 4.5 g. tert-BuOK in 80 ml. Me2SO, and adding 2.5 g. Me2SO4. The mixture is stirred 24 hrs. to give IV. A solution of 5 g. IV and 9 g. m-chloroperbenzoic acid in 50 ml. CHCl3 is refluxed 4 hrs. The cooled mixture is treated with H2O, and evaporated to give the 5-oxide, m. 197-8° (decomposition). At ambient temperature, 5 g. IV is dissolved in 25 ml. MeI. After 15 hrs., the excess MeI is evaporated to give the 5-Me quaternary derivative, m. 283-4°. Racemic IV (16.1 g.) and 22.9 g. dibenzoyl-L-tartaric acid are dissolved in hot iso-PrOH. H2O is added until the solution becomes turbid and the mixture left 2 days at 5°. The precipitate formed is separated, suspended in EtOH, and filtered to give a salt, m. 154-5° (iso-PrOH), [α]25D 292° (c 1.665, Me2SO,), which is decomposed with 1N NaOH and extracted with CHCl3 to give (+)-IV, m. 109-10° (C6H14), [α]27D 385° (c 1.8, EtOH). Similarly, using dibenzoyl-D-tartaric acid, the (-)-IV derivative, m. 110-11° (C6H14), [α]25D -368° (c 2.18, EtOH) is obtained. Addnl. I obtained are (R, R1, R2, and m.p. given): Et, H, 8-Cl, 58-9° (CHCl3); allyl, H, 8-Cl,-[(HCl salt, m. 214° (decomposition) (EtOH-Et2O)]; iso-Pr, H, 8-Cl,-[(b0.065 150-5°); maleate, m. 157-8° (iso-PrOH)]; Bu, H, 8-Cl, - (b0.5 154-7°), maleate m. 137-8°; CH2Ph, H, 8-Cl, (b0.008 180°), HCl salt, m. 200-2° (decomposition) (EtOH); Me2N(CH2)3, H, 8-Cl, (b0.003 190°), dimaleate m. 136-7° (iso-PrOH).

IT **16071-65-1P 17695-03-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16071-65-1 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepin-6(6aH)-one, 5-benzyl-2-chloro-5,7,8,9,10,12-hexahydro- (8CI) (CA INDEX NAME)



RN 17695-03-3 CAPLUS
CN Pyrido[2,1-c][1,4]benzodiazepin-6(5H)-one, 5-benzyl-2-chloro-6a,7,8,9,10,12-hexahydro-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl